UNSPSC 51151602: Benztropine or benzatropine

This classification denotes an antimuscarinic agent with the molecular formula C21H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NHL2J4X8K, chemically known as 8-azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo- (9ci) but generally known as benzatropine, which bears US NIH Compound Identifier 6832. Benzatropine most often comes in base and methanesulfonate forms. European Medicines Agency schedules Benzatropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05742MIG.

UNSPSC 51151602 Benztropine or benzatropine is a Commodity code that nominally covers a specific anticholinergic pharmaceutical, but recent state and local opportunities show little direct activity aligned with this code's narrow scope. The single substantive opportunity posted under or near this code — Seminole County, Florida's IFB for naloxone and drug deactivation systems (IFB60459723LAS, posted June 30, 2026) — involves procurement of emergency-response medications and harm-reduction equipment rather than benztropine itself. The Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) focuses on direct-to-manufacturer prescription fulfillment models and does not target any single pharmaceutical by name or therapeutic class. State and local governments do procure individual pharmaceuticals for public health, corrections, and community health programs, but the recent record under this code does not establish benztropine as an active procurement line in the state and local market.

Geographically, the limited activity spans Florida and Texas. Issuing bodies active in the recent opportunities include a county public health department (Seminole County) and a state health commission (Texas HHS), reflecting the typical buyers of pharmaceuticals at state and local level — health departments, corrections agencies, and integrated health systems. Without consistent recent solicitations specifically targeting benztropine, the code does not present a clear pipeline. Firms pursuing pharmaceutical contracts with state and local buyers should monitor broader pharmaceutical supply and GPO cooperative purchasing vehicles rather than await direct benztropine solicitations under this code.